Phase 2 trials in adults (46) and adolescents (47) demonstrated that crinecerfont significantly lowered ACTH, 17OHP and A4 concentrations after 14 days of open-label treatment, justifying that CRF1 antagonism has therapeutic value in CAH. Here, POMC is linked to congenital adrenal hyperplasia.